Manufacturer of Controlled Substances; Notice of Application, 21661 [2010-9559]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 79 / Monday, April 26, 2010 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2), authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations
§ 1301.34(a), this is notice that on March
4, 2010, Almac Clinical Services Inc.
(ACSI), 2661 Audubon Road, Audubon,
Pennsylvania 19403, has made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
Drug
Schedule
sroberts on DSKD5P82C1PROD with NOTICES
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Fentanyl (9801) ............................
II
II
II
The company plans to import small
quantities of the listed controlled
substances in dosage form to conduct
clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 26, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import the basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
VerDate Nov<24>2008
16:56 Apr 23, 2010
Jkt 220001
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: April 20, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–9562 Filed 4–23–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 5, 2010,
Stepan Company, Natural Products
Dept., 100 W. Hunter Avenue,
Maywood, New Jersey 07607, made
application by renewal to the Drug
Enforcement Administration (DEA) as a
bulk manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Cocaine (9041) .............................
Benzoylecgonine (9180) ...............
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 25, 2010.
Dated: April 20, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–9559 Filed 4–23–10; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
21661
DEPARTMENT OF JUSTICE
Federal Bureau of Investigation
Meeting of the CJIS Advisory Policy
Board
AGENCY: Federal Bureau of Investigation
(FBI), Department of Justice.
ACTION: Meeting notice.
SUMMARY: The purpose of this notice is
to announce the meeting of the Criminal
Justice Information Services (CJIS)
Advisory Policy Board (APB). The CJIS
APB is a federal advisory committee
established pursuant to the Federal
Advisory Committee Act (FACA). This
meeting announcement is being
published as required by Section 10 of
the FACA.
The CJIS APB is responsible for
reviewing policy issues and appropriate
technical and operational issues related
to the programs administered by the
FBI’s CJIS Division, and thereafter,
making appropriate recommendations to
the FBI Director. The programs
administered by the CJIS Division are
the Integrated Automated Fingerprint
Identification System, Interstate
Identification Index, Law Enforcement
Online, National Crime Information
Center, National Instant Criminal
Background Check System, National
Incident-Based Reporting System, Law
Enforcement National Data Exchange,
and Uniform Crime Reporting.
The meeting will be open to the
public on a first-come, first-seated basis.
Any member of the public wishing to
file a written statement concerning the
CJIS Division’s programs or wishing to
address this session should notify
Senior CJIS Advisor Roy G. Weise at
(304) 625–2730 at least 24 hours prior
to the start of the session. The
notification should contain the
requestor’s name, corporate designation,
and consumer affiliation or government
designation along with a short statement
describing the topic to be addressed and
the time needed for the presentation. A
requestor will ordinarily be allowed no
more than 15 minutes to present a topic.
DATES AND TIMES: The APB will meet in
open session from 8:30 a.m. until 5
p.m., on June 9–10, 2010.
ADDRESSES: The meeting will take place
at The Renaissance, A Columbus Hotel,
50 North Third Street, Columbus, Ohio
43215, telephone (614) 233–7519.
FOR FURTHER INFORMATION CONTACT:
Inquiries may be addressed to Mrs.
Margery E. Broadwater; Management
and Program Analyst; Advisory Groups
Management Unit, Law Enforcement
Support Section; FBI CJIS Division;
Module C3, 1000 Custer Hollow Road,
E:\FR\FM\26APN1.SGM
26APN1
]]>Agencies
[Federal Register Volume 75, Number 79 (Monday, April 26, 2010)]
[Notices]
[Page 21661]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-9559]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 5, 2010, Stepan
Company, Natural Products Dept., 100 W. Hunter Avenue, Maywood, New
Jersey 07607, made application by renewal to the Drug Enforcement
Administration (DEA) as a bulk manufacturer of the basic classes of
controlled substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cocaine (9041)............................. II
Benzoylecgonine (9180)..................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than June 25, 2010.
Dated: April 20, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-9559 Filed 4-23-10; 8:45 am]
BILLING CODE 4410-09-P
